ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01193933
Recruitment Status : Active, not recruiting
First Posted : September 2, 2010
Last Update Posted : March 7, 2018
Sponsor:
Information provided by (Responsible Party):
Elena N.Parovichnikova, National Research Center for Hematology, Russia

Brief Summary:
  1. evaluation of blast clearance in b/m after 7 days of prednisolone prephase and the efficacy of its substitution by dexamethasone if blast count is 25% and more
  2. feasibility for adults of "no interruptions" protocol with 8 weeks induction and 14 weeks consolidation followed by 2-years maintenance.
  3. tolerability and efficacy in adults of the prolonged L-asparaginase application (total proposed dose 560.000 IU)
  4. feasibility and efficacy of autologous stem cell transplantation for T-cell ALL

Condition or disease Intervention/treatment Phase
Ph-negative Adult Acute Lymphoblastic Leukemia Procedure: autologous HSCT Not Applicable

Detailed Description:
  1. The blast count in b/m after 7 days of prednisolone >25% was shown in 64% of patients. The substitution of prednisolone by dexamethasone did not influence survival.
  2. "no interruptions" induction was performed in 48% of patients.
  3. In 19% of patients the L-asparaginase therapy was stopped due to toxicity.
  4. Autologous stem cell transplantation was done in 20% of T-cell ALL patients.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 321 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Clinical Trial for Adult Ph-negative ALL. Evaluation of the Impact of the Prolonged L-asparaginase Therapy During Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity.
Study Start Date : November 2008
Actual Primary Completion Date : December 2016
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia
U.S. FDA Resources


Intervention Details:
    Procedure: autologous HSCT
    T-cell ALL patients recieve late consolidation with BEAM conditioning and stem cell support


Primary Outcome Measures :
  1. Proportion of adult ALL patients who tolerated the non-interrupted treatment [ Time Frame: 3 years ]
    Number of patients who finished the protocol without any deviation, who were off the protocol due to toxicity, in whom the treatment schedule was modified and respectively the antileukemia efficacy in those subgroups


Secondary Outcome Measures :
  1. Toxicity of prolonged L-asparaginase in adult patients [ Time Frame: 3 years ]
    Number of patients who tolerated the scheduled L-asparaginase by dose and time sequence, proportion of patients shifted to PEG-asparaginase, in whom L-asparaginase was stopped and, respectively, the survival without leukemia of those patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ph-negative precursors ALL
  • age 15-55 years
  • nontreated
  • Eastern Cooperative Oncology Group criterion status 0-3

Exclusion Criteria:

  • B-mature ALL
  • Ph-positivity
  • pretreatment
  • Eastern Cooperative Oncology Group criterion status 4

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01193933


Locations
Russian Federation
Russian Acute Lymphoblastic Leukemia Study group
Moscow, Russian Federation
Sponsors and Collaborators
National Research Center for Hematology, Russia
Investigators
Study Chair: Valeri G Savchenko, Professor National Research Center for Hematology

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Elena N.Parovichnikova, MD PhD, National Research Center for Hematology, Russia
ClinicalTrials.gov Identifier: NCT01193933     History of Changes
Other Study ID Numbers: ALL-2009
First Posted: September 2, 2010    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: March 2018

Keywords provided by Elena N.Parovichnikova, National Research Center for Hematology, Russia:
adult ALL
Ph-negative
dexamethasone
L-asparaginase

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Asparaginase
Antineoplastic Agents